Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
METTL1-mediated m7G modification of valine tRNAs drives metabolic adaptation in pancreatic ductal adenocarcinoma cells
Jiabei Zhu, Qi Zhang, Douglas Evans, Rui Su, Qiuhui Pan, Ajay Goel
Jiabei Zhu, Qi Zhang, Douglas Evans, Rui Su, Qiuhui Pan, Ajay Goel
View: Text | PDF
Research Article Gastroenterology Oncology

METTL1-mediated m7G modification of valine tRNAs drives metabolic adaptation in pancreatic ductal adenocarcinoma cells

  • Text
  • PDF
Abstract

Transfer RNA (tRNA) modifications play a critical role in regulating codon-specific mRNA translation and enabling tumor cell adaptation. The RNA methyltransferase 1 (METTL1) installs N7-methylguanosine (m7G) modifications on tRNAs, thereby shaping codon usage and translational output. However, the function and mechanistic contribution of the METTL1/tRNA axis in pancreatic ductal adenocarcinoma (PDAC) remain poorly defined. Here, we showed that METTL1 was overexpressed in PDAC tissues and that elevated METTL1 expression was associated with poor patient survival. Genetic ablation of METTL1 markedly suppressed PDAC cell proliferation, migration, and tumor growth in vitro and in vivo. Mechanistically, METTL1 loss selectively reduced m7G-modified valine tRNAs — particularly Val-AAC, Val-CAC, and Val-TAC — leading to impaired translation of valine-enriched OXPHOS transcripts. As a consequence, METTL1 deficiency disrupted mitochondrial respiration and energy production in PDAC cells. Consistent with this model, valine tRNA levels were elevated in PDAC tissues, and their selective depletion phenocopied METTL1 loss by impairing mitochondrial bioenergetics and tumor cell fitness. Thus, the METTL1/valine tRNA axis promoted PDAC progression through codon-dependent translational control of the mitochondrial electron transport chain and oxidative metabolism. Together, our findings identify a METTL1/tRNA/mitochondria signaling axis as a metabolic vulnerability and a promising therapeutic target in pancreatic cancer.

Authors

Jiabei Zhu, Qi Zhang, Douglas Evans, Rui Su, Qiuhui Pan, Ajay Goel

×

Figure 2

METTL1 promotes PDAC cell growth, migration, and tumorigenicity.

Options: View larger image (or click on image) Download as PowerPoint
METTL1 promotes PDAC cell growth, migration, and tumorigenicity.
(A) MET...
(A) METTL1-KO efficacy in BxPC-3 and MiaPaCa-2 Cas9 single clones. (B–D) Detection of proliferative activity by MTT assay (B and C) and colony formation assay (D) in control and METTL1-KO groups from BxPC-3 and MiaPaCa-2 cells. ***P < 0.001, by 2-way ANOVA followed by Dunnett’s multiple-comparison test (B and C) and 1-way ANOVA followed by Dunnett’s multiple-comparison test (D). (E) Detection of migration activity by wound-healing assay of BxPC-3 and MiaPaCa-2 cells at 0 hours and 24 hours in the control and METTL1-KO groups. ***P < 0.001, by 2-tailed, unpaired t test. (F) Images of mice and s.c. xenograft tumors derived from MiaPaCa-2 control and METTL1-KO cells (n = 5 mice per group). (G and H) Tumor growth curves (G) and tumor weights (H) for nude mice injected with MiaPaCa-2 control or METTL1-KO cells. **P < 0.01 and ***P < 0.001, by 2-way, repeated-measures ANOVA (G) and 2-tailed, unpaired t test (H). (I) Representative IHC images of H&E, METTL1, and Ki67 staining of dissected xenograft tumor tissues and quantification of the percentage of Ki67+ cells (n = 5 tumors per group). Original magnification, ×200 and ×400. Scale bars: 100 μm and 50 μm. ***P < 0.001, by 2-tailed, unpaired t test. Data are representative of 3 independent experiments. All data are presented as the mean ± SD.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts